NCT07159061Recruiting
Neurofeedback to Treat Depression - 2
Reducing Neural Perseveration Through Closed Loop Real Time fMRI Neurofeedback to Alleviate Depressive Symptoms
Source: ClinicalTrials.gov · Last updated 4 Dec 2025
Brief summary (registry, in English)
This study tests the efficacy of a new psychotherapeutic strategy for reducing negative attention bias (and therefore depression severity) in participants with MDD. This real-time fMRI neurofeedback therapy uses cloud-based pattern classification to decode a patient's attentional state and dynamically modulate task stimuli (in a closed loop) based on this state.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 3 Sept 2025
- Start date
- 21 Nov 2025
- Primary completion date
- 21 Nov 2028
- Lead sponsor
- University of Pennsylvania
- Diseases
- Depression
- NCT number
- NCT07159061
What you commit to
- Study type: Interventional
- Planned participants: 80
- From 21 Nov 2025 to the primary completion date, 21 Nov 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- MRI contraindications (medical implant, claustrophobia, etc.)
- Use of psychoactive medication (including antidepressants) or currently in therapy
Other illness
- Neurological disorder or any condition that in the view of the PI could impact brain data, cause depression, require medication that could cause depressive symptoms, or otherwise result in participant being unfit for study (for example, co-morbid psychotic, neurological disorders, developmentally or cognitively disabled/impaired, active alcohol or drug abuse/dependence within the past 6 months).
Age
- Outside age range
Other
- Pregnancy (female participants)
- Non-English speaking
- Non-correctable vision loss
- Refusal to provide informed consent
- representing an active suicide risk
Who the study is looking for
- Gender, inclusive
- Adult aged 18 - 65
- Meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for MDD according to the Clinician-Administered MDD Scale for DSM-5 (unipolar depression or bipolar II depressed)
- Scores at least a minimum score of 16 on Montgomery Asberg Depression Rating Scale (MADRS)
- Normal cognition
- Participants must be able to read and understand English
- Participants must be able to provide consent
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Center for Neuromodulation in Depression and Stress Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.